论文部分内容阅读
目的:研究非小细胞肺癌(NSCLC)组织中血管内皮因子(VEGF)的表达及其对预后的影响。方法:应用免疫组化SP法检测肺癌、癌旁及肺良性瘤样病变组织中VEGF的表达。结果:肺癌、癌旁及肺良性瘤样病变组织中VEGF的表达率为74.8%、46.3%和18.1%(P<0.05),VEGF阳性组术后生存明显短于阴性组(P<0.05)。VEGF的表达与年龄、性别、吸烟、癌组织类型、分化程度和不同临床分期均无明显关系(P>0.05),但与淋巴结转移有相关性(P<0.05)。结论:VEGF在肺癌组织中异常表达,且其表达与肺癌患者的预后有关,是判断预后的良好指标,可能成为非小细胞肺癌新的诊断标志及基因治疗的新靶点。
Objective: To study the expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC) and its effect on prognosis. Methods: Immunohistochemical SP method was used to detect the expression of VEGF in lung cancer, adjacent non-cancerous tissues and benign lung lesions. Results: The positive rates of VEGF expression in lung cancer, paracancer and benign pulmonary lesion were 74.8%, 46.3% and 18.1% respectively (P <0.05). The postoperative survival of the VEGF positive group was significantly shorter than that of the negative group (P <0.05). There was no significant correlation between VEGF expression and lymph node metastasis (P <0.05). There was no significant correlation between the expression of VEGF and age, sex, smoking, type of cancer, differentiation and different clinical stages (P> 0.05). Conclusion: The abnormal expression of VEGF in lung cancer and its expression is correlated with the prognosis of patients with lung cancer, which is a good indicator of prognosis. It may be a new diagnostic marker and a new target of gene therapy for non-small cell lung cancer.